Evaluation of the Antibacterial Activity of Green Propolis Extract and Meadowsweet Extract Against Staphylococcus aureus Bacteria: Importance in Wound Care Compounding Preparations | N/A | AlpaWash | |
Evaluation and Comparison of Wound Healing Properties of an Ointment (AlpaWash) Containing Brazilian Micronized Propolis and Peucedanum ostruthium Leaf Extract in Skin Ulcer in Rats | N/A | AlpaWash | |
Highlighting the Benefits of AlpaWash in Wound Care: Case Reports in Small Animals | N/A | AlpaWash | |
Case Report on the Effect of AlpaWash® on the Healing of a Post-surgical Wound in a Female Canine Initially Diagnosed with Pyometra | N/A | AlpaWash | |
How water activity can affect the stability of compounded non-sterile preparations | N/A | AlpaWash, CopaSil, Lipmax, Oleabase Plasticized, Ointment Base (Emulsifying), VersaPro Anhydrous Base, PolyPeg Suppository Base, SPG Supposi-Base, SPG Natural Supposi-Base, Witepsol H-15, CapsuBlend-H, CapsuBlend-P, CapsuBlend-S, Gum Base (Gelatin), Medi-RDT Base, Medi X-Tabb Base, NovaFilm Gel Base, Oral Mix Dry Alka, SF, Troche Base, Troche Base, NS, Chew-A-Treat (Compound A), Chew-A-Treat (Compound B), Chew-A-Treat (Compound C), Chew-A-Treat (Compound Kit A&B), Chew-A-Treat (Compound Kit A&C) | |
In Vitro Evaluation of Extemporaneously Compounded Immediate-release Capsules with Premixed Excipients, Based on the Biopharmaceutics Classification System (BCS) of the Drugs | Metronidazole, Theophylline, Levocarnitine | CapsuBlend-S, CapsuBlend-P, CapsuBlend-H | |
Antimicrobial Activity of Copaíba (Copaifera officinalis) and Pracaxi (Pentaclethra macrobola) Oils against Staphylococcus Aureus: Importance in Compounding for Wound Care | N/A | CopaSil | |
Prospective, Randomized, Double-Blind, Placebo-Controlled Study on Efficacy of Copaiba Oil in Silicone-Based Gel to Reduce Scar Formation | N/A | CopaSil | |
Case Report in Equine: Highlighting the Benefits of Medisca CopaSil in Burn-scar Management | N/A | CopaSil | |
Stability Evaluation of Minoxidil in Foamil Foam Base with Bracketing Study Design | Minoxidil | Foamil | |
Stability Assessment of Compounded Bracketed Estradiol 0.01-0.2%, Estriol 0.04-0.8%, Progesterone 1-20%, Testosterone 0.025-0.5% and DHEA 0.2-4% in Medisca HRT Cream Base | Estradiol, Estriol, Progesterone, Testosterone, DHEA | HRT Cream Base | |
Stability Assessment of Compounded Bracketed Estradiol 0.01-10% in Medisca HRT Cream Base | Estradiol | HRT Cream Base | |
Stability Assesment of Compounded Bracketed Estradiol 0.025-0.25%, Estriol 0.025-0.25% and Testosterone 1-10% in Medisca HRT Cream Base | Estradiol, Estriol, Testoterone | HRT Cream Base | |
Stability Assesment of Compounded Bracketed Estradiol 0.025-0.5%, Estriol 0.025-0.5% and Progesterone 1-20% in Medisca HRT Cream Base | Estradiol, Estriol, Progesterone | HRT Cream Base | |
Stability Assesment of Compounded Bracketed Estradiol 0.025-0.5% and Estriol 0.1-2% in Medisca HRT Cream Base | Estradiol, Estriol | HRT Cream Base | |
Stability Assessment of Compounded Bracketed Estriol 0.01-10% in Medisca HRT Cream Base | Estriol | HRT Cream Base | |
Stability Assessment of Compounded Bracketed Hydroquinone 2-10% in Medisca HRT Cream Base | Hydroquinone | HRT Cream Base | |
Stability Assessment of Compounded Bracketed Progesterone 1-40% in Medisca HRT Cream Base | Progesterone | HRT Cream Base | |
Stability Assessment of Compounded Bracketed Testosterone 0.02-25% in Medisca HRT Cream Base | Testosterone | HRT Cream Base | |
Homogenizing in Patient Applicating Device with MD Pump Adapter in MAZ Mixer | N/A | N/A | |